alexa Tocilizumab, Anti-Inflammatory Effect: New Indications? | Open Access Journals
ISSN: 2161-1025
Translational Medicine
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Tocilizumab, Anti-Inflammatory Effect: New Indications?

Machiel van den Akker*, Nadia Najafi and Jutte van der Werff ten Bosch

University Hospital Brussels, Pediatric Hematology Oncology, Belgium

*Corresponding Author:
Machiel van den Akker
University Hospital Brussels
Pediatric Hematology Oncology
Brussels, Belgium
Tel: + 31681387488
E-mail: [email protected]

Received Date: November 15, 2015 Accepted Date: December 16, 2015 Published Date: January 17, 2016

Citation: Akker M, Najafi N, Bosch JW (2016) Tocilizumab, Anti-Inflammatory Effect: New Indications?. Transl Med (Sunnyvale) 6:165. doi: 10.4172/2161-1025.1000165

Copyright: © 2016 Akker M et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Translational Medicine

Short Communication

Tocilizumab is a humanizedmonoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor. The inhibition of this receptor complex prevents IL-6 signal transduction to inflammatory mediators, hence to the entire proinflammatory properties of B and T cells [1,2]. Tocilizumab is indicated both for the treatment of moderately to severely active rheumatoid arthritisin adults and for the treatment of active polyarticular juvenile idiopathic arthritis and active systemic juvenile idiopathic arthritis in children older than 2 years of age [3].

Multicentric Castleman disease is associated with significant systemic symptoms, in part related to the underlying role of IL-6 in disease pathogenesis. Turcotte et al show a case who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with tocilizumab [4]. This drug has also been given as part of a immunosuppressive intervention for severe acute graft-versus-host-disease after allogeneic stem cell transplantation with improvement of the clinical symptoms within 48hr [1]. Although not yet explored, there may be also a window of opportunity to suppress other inflammatory processes. We present briefly the case of an adolescent girl with relapsed acute lymphoblastic leukaemia who was admitted to the hospital with neutropenic fever. She developed tachycardia and hypotension and was transferred to pediatric intensive care unit where she was started on inotropic support. Her blood cultures grew Candida tropicalisfor which her Hickman catheter was removed and extensive anti-microbial treatment including vancomycin, meropenem, caspofungin, ambisome and fluconazole, was initiated. Both G-CSF (ANC (=Absolute Neutrophil Count) 150) and methylprednisolone (2 mg/kg/day) were subsequently added to the treatment. However, her clinical course continued to worsen and developed multi-organ failure requiring maximal intensive care support, including high frequency oscillatory ventilation, nitric oxide inhalation, further extending inotropic support with epinephrine, norepinephrine and dobutamine, and continuous renal replacement therapy. While her neutrophil count improved (ANC 10.000, G-CSF was discontinued), her respiratory condition worsened, making it more difficult to ventilate her. Assuming the likelihood of the systemic inflammatory response due to ongoing IL-6 production (secondary to the systemic Candida tropicalis infection), Tocilizumab (10 mg/kg) was administered intravenously over 1 hour (72 hours after the G-CSF was discontinued). Within 12 hours, the chest X-ray showed a more convenient air distribution in the lungs (Figure 1) and the ventilatory support could be weaned. Unfortunately she experienced only a transient response. The next day her condition worsened, she became anuric and her cardiac function deteriorated further. Soon thereafter she passed away. Whether the administration of Tocilizumab in an earlier stage would have led to a better outcome, remains unclear. Conclusion: though our finding is limited to one single patient, the transient improvement of her condition may suggest potential efficacy of Tocilizumab in children with systemic inflammatory response of other causes.

translational-medicine-chest-x-ray

Figure 1: The chest X-ray showed a more convenient air distribution in the lungs.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 7778
  • [From(publication date):
    March-2016 - Jun 29, 2017]
  • Breakdown by view type
  • HTML page views : 7738
  • PDF downloads :40
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords